Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

NIH

Sponsor class

Conditions

Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
DRUG: Osimertinib
PROCEDURE: Radiologic Examination

Sponsor

National Cancer Institute (NCI)